Worth knowing, even if we suppose that the key to beat prostate cancer is a combo therapy...
"Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a lower risk of treatment discontinuation and disease progression if they receive darolutamide rather than other androgen receptor inhibitors, according to a study published in JAMA Network Open."
Thank you for this information.
How is it "worth knowing"? How do you explain this?:
"This anchored MAIC analysis of pivotal phase 3 studies in patients with nmCRPC suggests that apalutamide + ADT is more effective than darolutamide + ADT for MFS, progression-free survival (PFS), and prostate-specific antigen (PSA) progression, with a similar OS benefit and tolerability profile."
pubmed.ncbi.nlm.nih.gov/347...
The problem with posting this kind of garbage is that patients with no background in research think it's true. It is not worth knowing and may do harm.
As I said, must be taken with a pinch of salt because it's sponsored by Bayer, but the study has been published on many scientific journals and presented at ASCO 2023
ascopubs.org/doi/10.1200/JC...
No, it's not because it's sponsored by Bayer - all drug trials are sponsored be pharmaceutical companies. It's garbage for patients because it's retrospective. Most research is done for the purposes of hypothesis generation for other researchers, not for patients. Retrospective studies do NOT tell patients anything useful. That's why I never posted that or the equally useless study showing apalutamide is better than darolutamide that I linked above. Retrospective studies are usually wrong because patients were selected to get one drug or another because of their characteristics - it's called "selection bias.". This cannot be corrected for using propensity score matching or inverse-weighting.
I should remove it then!
I think it is better to leave up with my comments. The genie is out of the bottle. Patients often use Dr Google to find studies that confirm their biases. I think it is better to educate patients about why one study may be useful, but another is only so much garbage.
I normally fully agree with you TA.But reading your comment and noting your uncommon hostility plus the single word "suggests" gives me pause to say Nubeqa seems a good choice to be considered.
No study guarantees long term positive results, or at least none I have read.
The word "suggests" should always be used for retrospective studies. Only a prospective randomized trial can "prove" anything. My hostility is directed at using retrospective studies to provide proof.
I agree that Nubeqa is a good choice for non-metastatic CRPC. But so is Erleada, Xtandi and Zytiga. And there is no information that proves one is better than any other, which is my point.
I hope there will someday be a comparative randomized trial, but pharmaceutical manufacturers will not sponsor it (they don't want to risk being a loser). I've heard a group in the UK is considering sponsoring one. It is very frustrating for patients, but when you think about it, an embarrassment of riches is a good problem to have.
Your last sentence is right on point.
I personally believe that Nubeqa is great for nmCRPC because it was designed for it.
I am not sure if I would myself use Nubeqa mainly because I have a metastases in my neck and as we all know Nubeqa was designed not to cross the blood brain barrier therefore because my metastases is in my neck that is a design flow.
If your cancer is still in your prostate only they can design Nubeqa to have a very strong effect without a side effects because it will not cross the blood brain barrier.
That is a big advantage of Nubeqa but for me it is a big concern because it will have no effect on on the prostate cancer cells if they cross into my brain. Even if you have a triplet therapy with Nubeqa, docetaxel and Degarelix you could and up with the cancer in your brain. I believe Nubeqa is great for nmCRPC but would be risky for me with the metastases in my neck.
Your perspective on Nubeqa (darolutamide) makes sense, especially given its design. Nubeqa is highly effective for non-metastatic castration-resistant prostate cancer (nmCRPC) due to its inability to cross the blood-brain barrier, which reduces central nervous system-related side effects, a key advantage for many patients. However, your concern about its limitations in addressing metastases near the neck is valid, as neck metastases could potentially indicate spread toward areas where crossing the blood-brain barrier might be crucial for treatment efficacy.
Given your metastatic neck involvement, the risk of brain metastases does bring up a unique challenge. Even though the combination of Nubeqa with docetaxel and Degarelix offers a powerful triple therapy option, as you pointed out, it might not protect against brain involvement in your case. This is where alternative treatments that can cross the blood-brain barrier, like abiraterone or enzalutamide, may provide more comprehensive coverage against potential spread to the brain.
Your insight shows a deep understanding of how treatment selection should be personalized based on metastases location and the specific properties of the drugs. Balancing the potential benefits of Nubeqa's safety with its limitations in certain metastatic scenarios like yours is critical.
Quercetin & AR-V7.
Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells
